标题
Structure and Optimization of Checkpoint Inhibitors
作者
关键词
-
出版物
Cancers
Volume 12, Issue 1, Pages 38
出版商
MDPI AG
发表日期
2019-12-23
DOI
10.3390/cancers12010038
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy of nivolumab four-weekly dosing schedule based on body weight
- (2019) Mário L de Lemos et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma
- (2019) Sascha Rahn et al. Oncotarget
- Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
- (2019) Y Bi et al. ANNALS OF ONCOLOGY
- A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy
- (2019) Pottayil G Sasikumar et al. MOLECULAR CANCER THERAPEUTICS
- The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
- (2019) Anne Månsson Kvarnhammar et al. Journal for ImmunoTherapy of Cancer
- CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
- (2019) Bogdan Musielak et al. MOLECULES
- Changing body weight–based dosing to a flat dose for avelumab in metastatic Merkel cell and advanced urothelial carcinoma
- (2019) Ana M. Novakovic et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
- (2019) Karen A. Autio et al. CLINICAL CANCER RESEARCH
- Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
- (2019) Petros Fessas et al. IMMUNOLOGY
- Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
- (2019) Samuel J. Klempner et al. ONCOLOGIST
- Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
- (2019) Zuzana Macek Jilkova et al. Cancers
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction
- (2018) Rebecca J. Boohaker et al. CANCER LETTERS
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
- (2018) Paul G. Baverel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
- (2018) Natasha A. Pereira et al. mAbs
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263
- (2018) Enrico Munari et al. Oncotarget
- Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts
- (2018) Christoph Goletz et al. Frontiers in Immunology
- M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
- (2018) Karin M. Knudson et al. OncoImmunology
- Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
- (2018) G V Long et al. ANNALS OF ONCOLOGY
- Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
- (2018) Elizabeth Ahern et al. Nature Reviews Clinical Oncology
- Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs)
- (2018) Sorim Nam et al. Biomolecules & Therapeutics
- Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
- (2018) George Fromm et al. Journal for ImmunoTherapy of Cancer
- Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
- (2017) Katarzyna Guzik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
- (2017) Hongshan Li et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
- (2017) Udupi A. Ramagopal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
- (2017) Krzysztof M. Zak et al. STRUCTURE
- An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
- (2017) Shuguang Tan et al. Nature Communications
- Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
- (2017) Fei Zhang et al. Oncotarget
- PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
- (2017) Enrico Munari et al. Oncotarget
- Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells
- (2017) Masahiro Okada et al. Cell Reports
- Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
- (2017) Shuguang Tan et al. Protein & Cell
- Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
- (2017) Chunlin Li et al. Cancer Immunology Research
- Evaluation of dosing strategy for pembrolizumab for oncology indications
- (2017) Tomoko Freshwater et al. Journal for ImmunoTherapy of Cancer
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
- (2017) Hyun Tae Lee et al. Scientific Reports
- Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
- (2016) Kefang Liu et al. CELL RESEARCH
- Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
- (2016) Zhenkun Na et al. CELL RESEARCH
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
- (2016) Krzysztof M. Zak et al. Oncotarget
- Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
- (2016) Shruti Agrawal et al. Journal for ImmunoTherapy of Cancer
- High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
- (2016) Shoichiro Horita et al. Scientific Reports
- Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy
- (2015) Hao-Nan Chang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
- (2015) Giovanna Scapin et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
- (2015) Giovanna Scapin et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
- (2015) Ruea-Yea Huang et al. Oncotarget
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
- (2015) M. Callea et al. Cancer Immunology Research
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
- (2014) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
- (2014) Yan Feng et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
- (2014) A. L. Kinter et al. JOURNAL OF IMMUNOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
- (2013) Y. Feng et al. CLINICAL CANCER RESEARCH
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events
- (2013) Pottayil Sasikumar et al. Journal for ImmunoTherapy of Cancer
- Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
- (2012) David L. Lacey et al. NATURE REVIEWS DRUG DISCOVERY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection
- (2010) T. Watanabe et al. JOURNAL OF VIRAL HEPATITIS
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
- (2008) D. Y.-w. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
- (2008) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now